CSIMarket
 


Hillevax Inc   (HLVX)
Other Ticker:  
 

Hillevax Inc 's Leverage Ratio

HLVX's quarterly Leverage Ratio and Total Liabilities, Equity growth


Despite a net increase in borrowings by 0.86%, Hillevax Inc managed to enhance Leverage Ratio in the third quarter 2023 to 0.23, surpassing the average for Hillevax Inc 's Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the third quarter 2023, 50 other companies have achieved lower Leverage Ratio than Hillevax Inc in the III Quarter 2023. While Leverage Ratio total ranking has improved so far in the third quarter 2023 to 514, from total ranking in the second quarter 2023 at 655 .

Explain Leverage Ratio?
Who are HLVX Customers?
What are HLVX´s Total Liabilities?


HLVX Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change 3.98 % -27.84 % - - -
Y / Y Total Liabilities Change 95.91 % 77.95 % -79.55 % - -
Leverage Ratio MRQ 0.23 0.31 0.24 0.19 0.12
HLVX's Total Ranking # 514 # 655 # 541 # 316 # 322
Seq. Equity Change 36.51 % -10 % -9.04 % -6.95 % -5.26 %
Seq. Total Liabilities Change 0.86 % 17.03 % 15.84 % 43.28 % -8.39 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 51
Healthcare Sector # 259
Overall Market # 514


Leverage Ratio Statistics
High Average Low
0.31 0.2 0.12
(Jun 30 2023)   (Sep 30 2022)




Financial Statements
Hillevax Inc 's Equity $ 299 Millions Visit HLVX's Balance sheet
Hillevax Inc 's Total Liabilities $ 68 Millions Visit HLVX's Balance sheet
Source of HLVX's Sales Visit HLVX's Sales by Geography


Cumulative Hillevax Inc 's Leverage Ratio

HLVX's Leverage Ratio for the trailling 12 Months

HLVX Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth 3.98 % -27.84 % - - -
Y / Y Total Liabilities TTM Growth 95.91 % 77.95 % -79.55 % - -
Leverage Ratio TTM 0.24 0.21 0.16 0.59 0.84
Total Ranking TTM # 497 # 473 # 399 # 1489 #
Seq. Equity TTM Growth 36.51 % -10 % -9.04 % -6.95 % -5.26 %
Seq. Total Liabilities TTM Growth 0.86 % 17.03 % 15.84 % 43.28 % -8.39 %


On the trailing twelve months basis Due to the net new borrowings of 0.86% during the trailing twelve months finishing in the III Quarter 2023, cumulativeLeverage Ratio improved to 0.24, below the Hillevax Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry HLVX recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 20, from total ranking in previous 12 month period at 3.

Explain Leverage Ratio?
Who are HLVX Customers?
What are HLVX´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 1
Within the Market # 514


trailing twelve months Leverage Ratio Statistics
High Average Low
0.59 0.3 0.16
(Dec 31 2022)   (Mar 31 2023)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Sangamo Therapeutics Inc   0.63 $ 84.775  Millions$ 134.922  Millions
Coeptis Therapeutics Holdings Inc   0.63 $ 2.752  Millions$ 4.393  Millions
Ginkgo Bioworks Holdings Inc   0.62 $ 773.709  Millions$ 1,252.683  Millions
Zura Bio Limited  0.62 $ 39.837  Millions$ 64.755  Millions
Elevation Oncology inc   0.60 $ 37.559  Millions$ 62.416  Millions
Senti Biosciences Inc   0.59 $ 48.830  Millions$ 82.936  Millions
Inmune Bio Inc   0.57 $ 25.155  Millions$ 43.933  Millions
Lineage Cell Therapeutics Inc   0.57 $ 38.036  Millions$ 66.660  Millions
Aligos Therapeutics Inc   0.57 $ 31.031  Millions$ 54.821  Millions
Vericel Corporation  0.56 $ 113.745  Millions$ 204.380  Millions
C4 Therapeutics Inc   0.54 $ 116.989  Millions$ 216.024  Millions
Miromatrix Medical inc   0.51 $ 7.879  Millions$ 15.542  Millions
Vaxart Inc   0.48 $ 34.121  Millions$ 71.521  Millions
Moderna Inc   0.45 $ 5,995.000  Millions$ 13,455.000  Millions
Qiagen N v   0.44 $ 1,692.857  Millions$ 3,807.764  Millions
Recursion Pharmaceuticals Inc   0.44 $ 192.858  Millions$ 437.967  Millions
Neurocrine Biosciences Inc   0.42 $ 846.100  Millions$ 2,002.100  Millions
Scholar Rock Holding Corp  0.41 $ 69.489  Millions$ 167.665  Millions
Instil Bio Inc   0.40 $ 94.426  Millions$ 234.024  Millions
Editas Medicine Inc   0.40 $ 144.188  Millions$ 360.462  Millions
Tscan Therapeutics Inc   0.39 $ 65.380  Millions$ 168.961  Millions
Ikena Oncology Inc   0.39 $ 59.991  Millions$ 155.344  Millions
Seagen Inc   0.37 $ 954.716  Millions$ 2,550.421  Millions
Monte Rosa Therapeutics Inc   0.37 $ 67.579  Millions$ 184.524  Millions
Sophia Genetics Sa  0.36 $ 54.714  Millions$ 151.442  Millions
Bioatla Inc   0.36 $ 34.006  Millions$ 94.703  Millions
Cognition Therapeutics inc   0.34 $ 9.846  Millions$ 28.926  Millions
Passage Bio inc   0.34 $ 42.980  Millions$ 126.276  Millions
Organovo Holdings Inc   0.32 $ 2.705  Millions$ 8.456  Millions
Fusion Pharmaceuticals Inc   0.31 $ 58.740  Millions$ 188.471  Millions

Date modified: 2023-11-12T11:31:51+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com